Upstream Bio, Inc.
UPB$1.67B
Small CapNASDAQBiotechnology🇺🇸North America52 employees
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Feb 19, 2026
11dData is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply
Market Overview
Stock performance and market intelligence
Catalyst Timeline
1 upcoming, 0 past
Phase 2Next
Verekitug (UPB-101) Phase 2 Results Expected
Feb 19, 2026Verekitug (UPB-101)479
Primary completion for Verekitug (UPB-101) trial (NCT06196879) in Severe Asthma
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Drug Pipeline
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
Verekitug (UPB-101) | Phase 2 | Chronic Rhinosinusitis With Nasal Polyps | - |
Verekitug | Phase 2 | Severe Asthma | - |
Regulatory & News
Approvals, filings, and latest developments
Regulatory Approvals
UPB News